The Power of Pharmacist Interventions in Improving Glycemic Control for Diabetes Patients: A Multicenter Study in Malaysia

By Staff Writer

July 10, 2023

A recent study conducted in Malaysia has shed light on the significant impact of pharmacist interventions on glycemic control in diabetic patients. The study, which focused on the Diabetes Medication Therapy Adherence Clinic (DMTAC) program, revealed a substantial reduction in HbA1c levels among patients after their visits to the clinic.

The findings of this study were consistent with previous smaller-scale studies conducted in a health clinic and a tertiary hospital in Malaysia. These studies also demonstrated a significant reduction in HbA1c levels among diabetic patients. Additionally, the study found that patients who did not default from follow-up visits achieved significantly lower HbA1c levels compared to those who did default.

Several factors were identified as independent predictors of HbA1c levels, including the frequency of DMTAC visits, duration of diabetes, number of dosage adjustments, and the use of antidiabetic agents. The study also highlighted the overall improvement in HbA1c levels among all subjects, including the defaulters, from baseline until post-2 (up to a year).

The study emphasized the need for adherence to follow-up schedules in diabetes clinics, as patients who adhered to DMTAC follow-up experienced a greater reduction in HbA1c levels. It also highlighted the potential benefits of a more holistic and multidisciplinary approach to treating diabetic patients, such as combining different clinics and reducing the number of follow-ups.

While there was no significant difference in glycemic control between patients who visited DMTAC in hospitals and primary health clinics, a higher default rate was observed in hospital patients. This suggests the need to strengthen primary health care and optimize its utilization among diabetes patients.

The study also analyzed the predictors that led to HbA1c reduction and found that more frequent DMTAC visits during the initial phase had a positive impact on glycemic control. However, this impact was not observed in the second phase of follow-up. Optimization of diabetic treatment, particularly through pharmacist-led interventions such as dosage adjustment and the addition of antidiabetic agents, significantly improved glycemic control in the longer term.

This real-world study provides valuable insights into the factors and interventions associated with improved glycemic control in diabetes patients. It highlights the crucial role of pharmacists in diabetes care and offers guidance to policymakers in determining key performance indicators in DMTAC.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.